Clinical Trials Logo

Filter by:
NCT ID: NCT04380532 Active, not recruiting - Covid19 Clinical Trials

Tableted COVID-19 Therapeutic Vaccine

COVID-19
Start date: May 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Safety and immunogenicity one-month study in healthy individuals administered once-daily pill of therapeutic vaccine made from heat-inactivated plasma from donors with COVID-19. Healthy, at least 20, volunteers will be monitored for signs of adverse events. Their PBMC will be collected at baseline and one month later to analyze which type of immune response vaccine has induced.

NCT ID: NCT04377243 Not yet recruiting - Clinical trials for Renal Failure Chronic

Immunotherapy of Chronic Kidney Failure

Start date: June 16, 2020
Phase: Phase 2
Study type: Interventional

Kidney failure can result from inflammatory renal disease in the context of autoimmunity because the kidney is targeted by host's immune response against self. There are many causes to this, but abnormal kidney function tests, i.e., BUN and creatinine, can reveal the disease. Oral delivery of kidney cells is ought to produce the immune tolerance - phenomenon is known as oral tolerance. Preliminary studies produced convincing evidence that this hypothesis holds true and has not produced any adverse side effects. Intended open label Phase II aims to confirm these findings.

NCT ID: NCT04305704 Recruiting - Vascular Diseases Clinical Trials

Coated Mongolian Aneurysm Treatment Study 2

COMATS 2
Start date: February 8, 2020
Phase:
Study type: Observational

The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under prasugrel.

NCT ID: NCT04305626 Recruiting - Vascular Diseases Clinical Trials

Coated Mongolian Aneurysm Treatment Study 1

COMATS 1
Start date: June 22, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under Dual Antiplatelet Medication.

NCT ID: NCT04126135 Not yet recruiting - Nicotine Addiction Clinical Trials

Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy

Start date: October 2019
Phase: Phase 3
Study type: Interventional

A pragmatic, single blinded, randomized, controlled non-inferiority trial of Cytisine versus Nicotine Replacement Therapy for continuous abstinence is conducted in the government run primary health hospitals in Mongolia.

NCT ID: NCT03916757 Recruiting - Clinical trials for Glioblastoma Multiforme

V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer

GBM
Start date: April 16, 2019
Phase: Phase 2
Study type: Interventional

The Phase II study to determine the safety and efficacy of V-Boost in treating a type of brain cancer called Glioblastoma Multiforme (GBM). V-Boost is an immunotherapy in which the patient's immune system will be modulated to eliminate tumor cells. V-Boost is made as an oral tablet which contains specially formulated hydrolyzed GBM antigens along with alloantigens. Patients are either newly diagnosed or with recurrent form of GBM who may have been subjected to surgery and/or chemo- or radiation therapy that ended up unsuccessful. The goal is to eradicate GBM tumor cells through daily oral administration of one pill of V-Boost immunotherapeutic vaccine, which so far has not shown any adverse reaction.

NCT ID: NCT03719313 Recruiting - Clinical trials for Hepatitis Delta Virus

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

D-LIVR
Start date: December 1, 2018
Phase: Phase 3
Study type: Interventional

Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral suppression and alanine aminotransferase (ALT) normalization. For each LNF-containing regimen, a composite endpoint of EOT (48 weeks) virologic response and ALT normalization will be used. Virologic response will be defined as a 2 log10 IU/mL reduction from baseline.

NCT ID: NCT03572361 Recruiting - Breast Cancer Clinical Trials

Open Label Immunotherapy Trial for Breast Cancer

V3-MOMMO
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

This Phase II will evaluate a new type of breast cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. Investigators will test new tableted preparation, V3-MOMMO, obtained from hydrolyzed, inactivated blood and tumors of patients with breast cancer. Study will last 3 months, 20 patients will be recruited, given one pill per day for three months. The primary clinical endpoint is effect on tumor size and burden after 3 months. Secondary endpoint will be effect on levels of tumor markers on monthly basis compared to baseline.

NCT ID: NCT03556566 Recruiting - Ovarian Cancer Clinical Trials

Open Label Immunotherapy Trial for Ovarian Cancer

V3-OVA
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

This Phase II will evaluate a new type of ovarian cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. We will test new tableted preparation, V3-OVA, obtained from hydrolyzed, inactivated blood and tumors of patients with cancer of ovaries. Study will last 3 months, 20 patients will be recruited, given one pill per day for three months. The primary clinical endpoint is effect on tumor size and burden after 3 months. Secondary endpoint will be effect on levels of tumor markers on monthly basis compared to baseline.

NCT ID: NCT03550755 Recruiting - Cervical Cancer Clinical Trials

Immunotherapy of Cervical Cancer With V3-Cervix

V3-Cervix
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

The goal of this trial is to evaluate the efficacy of immunotherapy for cervical cancer based on a fundamentally new approach. We will test new tableted preparation, V3-Cervix, obtained from hydrolyzed, inactivated blood and tumors of patients with cervical cancer. When administered orally, it should cause a specific anti-tumor immune response and an anti-inflammatory effect. Trial is planned to last 3 months, recruit 20 volunteers, administer daily pill of vaccine and evaluate effect on tumor size and tumor markers.